Skip to Content

It’s an Evolutionary Arms Race, and the Superbugs are Winning

An exhaustive new report on the state of drug-resistance in microbes has found that by 2050, infections could kill more people a year than cancer.

It’s time to start doing something about superbugs. A massive new report commissioned by the U.K. government has found that, if left unchecked, by the middle of this century drug-resistant bacteria could kill 10 million people a year—more than currently die of cancer. The costs to the global economy could run to $100 trillion by 2050. It’s one of the greatest threats to global health that we face.

And yet the problem has garnered much less attention than it would seem to warrant. According to economist Jim O’Neill, who led the study at the behest of U.K. prime minister David Cameron, no fundamentally new classes of antibiotic drugs have been developed since the 1950s, and the means of diagnosing bacterial infections remains largely unchanged since the 19th century.

The report’s authors outline a 10-point plan for stopping the coming plague. Many of the measures they outline are straightforward, like improved sanitation, monitoring of how often antibiotics are prescribed, and reducing their use in agriculture (where they are applied prodigiously, both to stop infection and promote growth in livestock).

Such tactics have the potential to make a huge impact. Take poor sanitation as an example: the study estimates that just four countries—India, Nigeria, Indonesia, and Brazil—use 500 million courses of antibiotics each year to combat diarrhea. Cleaning up water supplies could cut that figure by 60 percent. That would be 300 million fewer times bacteria are exposed to our arsenal of germ-killing drugs, and far less opportunity for the bugs to evolve resistance.

Of course, the arsenal could always be expanded, but pharmaceutical companies have to invest heavily in bringing a drug to market. Once they do, they face the challenge of trying to recoup what are often hundreds of millions of dollars in R&D costs and turn a profit—while not making the problem worse by flooding the market with their new compound and giving bugs a chance to develop resistance anew. It should come as little surprise that firms are reluctant to play this game.

Here, too, the report suggests a potentially powerful solution: pay companies big bucks to develop new antibiotics. In their proposal, the authors suggest financial incentives from $800 million to $1.3 billion per drug that would be paid on top of sales revenue for companies to research and produce new weapons in the fight against superbugs.

If that sounds expensive, the report argues, it’s nothing compared to the cost of inaction.

(Read more: The Atlantic, The Economist)

Keep Reading

Most Popular

AV2.0 autonomous vehicles adapt to unknown road conditions concept
AV2.0 autonomous vehicles adapt to unknown road conditions concept

The big new idea for making self-driving cars that can go anywhere

The mainstream approach to driverless cars is slow and difficult. These startups think going all-in on AI will get there faster.

biomass with Charm mobile unit in background
biomass with Charm mobile unit in background

Inside Charm Industrial’s big bet on corn stalks for carbon removal

The startup used plant matter and bio-oil to sequester thousands of tons of carbon. The question now is how reliable, scalable, and economical this approach will prove.

AGI is just chatter for now concept
AGI is just chatter for now concept

The hype around DeepMind’s new AI model misses what’s actually cool about it

Some worry that the chatter about these tools is doing the whole field a disservice.

images created by Google Imagen
images created by Google Imagen

The dark secret behind those cute AI-generated animal images

Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.